Clinical Scorecard: The 50th Annual Conference of the European Society for Blood and Marrow Transplantation: Recognition of Van Bekkum Award Recipients

At a Glance

Key Highlights

• Advances in haploidentical stem cell transplantation improving survival in high-risk acute myeloid leukemia.
• Development of engineered T-lymphocytes and TCR gene editing for targeted anti-leukemia immunotherapy without inducing GvHD.
• Use of mesenchymal stem cells and defibrotide for treatment and prevention of severe GvHD and hepatic veno-occlusive disease (VOD).

Guideline-Based Recommendations

Diagnosis

• Use of gene expression profiling and genetic mutation analysis (e.g., NOD2/CARD15) to assess risk of GvHD and transplant-related mortality.
• Monitoring of KIR ligand mismatching to predict relapse risk and survival outcomes.

Management

• Application of autologous and allogeneic stem cell transplantation tailored to disease risk and donor compatibility.
• Implementation of immuno-gene therapy using tumor mRNA transfected dendritic cells and engineered T-cells targeting leukemia antigens.
• Prophylactic transfer of leukemia-reactive donor T-cells post-transplant to reduce relapse.
• Use of mesenchymal stem cells for treatment of severe acute and chronic GvHD.
• Administration of defibrotide to prevent hepatic VOD in high-risk pediatric patients.

Monitoring & Follow-up

• Regular assessment of disease relapse and survival post-transplantation.
• Monitoring for development of GvHD and transplant-related complications.
• Long-term follow-up for persistence and efficacy of engineered T-cell therapies.

Risks

• Risk of GvHD associated with genetic mutations in recipients and donors.
• Potential relapse and death linked to single nucleotide polymorphisms in transplant recipients.
• Complications related to hepatic VOD and immune reconstitution.

Patient & Prescribing Data

Patients undergoing hematopoietic stem cell transplantation for hematologic malignancies and related disorders.

Emerging therapies including gene-modified T-cells and immuno-gene therapy show promise in reducing relapse and improving survival without increasing GvHD.

Clinical Best Practices

• Selecting donors based on KIR ligand compatibility to improve transplant outcomes.
• Incorporating genetic screening for mutations associated with GvHD risk in donor and recipient evaluation.
• Utilizing mesenchymal stem cells and defibrotide as adjunct therapies for managing transplant-related complications.
• Employing engineered T-cell therapies targeting specific leukemia antigens to enhance graft-versus-leukemia effect.
• Conducting multidisciplinary long-term follow-up to monitor efficacy and adverse effects of novel therapies.

References

• European Society for Blood and Marrow Transplantation Annual Meeting